Literature DB >> 26719547

NONOBSTRUCTIVE AZOOSPERMIA, FOLLICLE-STIMULATING HORMONE AS A MARKER OF SUCCESSFUL SPERM RETRIEVAL.

A Khelaia1, Z Saker1, O Tsintsadze1, L Managadze1.   

Abstract

Testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) was revolutionized treatment of infertile men with azoospermia. Predictive factors for the presence of spermatozoa in testis are still under debate. Serum FSH levels reflect the state of seminiferous epitelium. Serum FSH has been evaluated as a predictor of success sperm retrieval rate (SRR) in NOA (37 cases 46XY men), but even among men with the highest FSH (30,0 - 40,0 mU/ml) spermatozoon was found. Men with FSH serum level 10 - 15 mU/ml had the SRR 0%. TESA is as a simple, minimally invasive approach for sperm retrieval. In our study sperm retrieval rate was 46%. In our practice we advised TESA as a first step and FSH can predict the success. TESA it is not only a diagnostic procedure to define the level of spermatogenesis, but also a therapeutic technique to retrieve sperm for ICSI. Also, in cases of negative results after TESE and hypospermatogenesis by histopatology we advised re-TESA after 3-6 months.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26719547

Source DB:  PubMed          Journal:  Georgian Med News        ISSN: 1512-0112


  2 in total

1.  Testis spectroscopy may predict sperm retrieval rate in men with non-obstructive azoospermia undergoing micro-TESE: A pilot study

Authors:  Önder Çelik; Şafak Hatırnaz; Aynur Erşahin; Alper Başbuğ; Gonca Yetkin Yıldırım; Vahit Özener; Neslihan Gürpınar; Sudenaz Çelik; Nilüfer Çelik; Tansu Küçük; Cihat Ünlü
Journal:  J Turk Ger Gynecol Assoc       Date:  2019-10-23

2.  Predictive significance of serum inhibin B on testicular haploid gamete retrieval outcomes in nonobstructive azoospermic men.

Authors:  Zhi-Guo Zhu; Zhi-Gang Zhao; Qing-Yang Pang; Tong Chen; Jian-Min Zhang; Tai-Jian Zhang; Chao Xu; Hao-Bo Zhang; Wen Liu; Xu-Jun Xuan
Journal:  Asian J Androl       Date:  2019 Mar-Apr       Impact factor: 3.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.